NCT04318938: Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping |
|
|
| Active, not recruiting | 2 | 118 | Europe | Brigatinib, Study treatment, Tyrosine kinase inhibitor | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Thoraxklinik-Heidelberg gGmbH, Takeda | NSCLC | 01/26 | 01/26 | | |
PYNNACLE, NCT04585750: The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation |
|
|
| Recruiting | 1/2 | 230 | Europe, US, RoW | PC14586, rezatapopt, pembrolizumab, KEYTRUDA®, MK-3475, KEYNOTE-D79, MK-3475-D79 | PMV Pharmaceuticals, Inc, Merck Sharp & Dohme LLC | Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer | 03/26 | 07/26 | | |
